SCHEMBL10076403

SCHEMBL10076403

COC(=O)C(N)Cc1ccc(C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
ATM Q13315 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
ACACB O00763 1/20 0.45
SLC7A5 Q01650 3/20 0.44
PTGS2 P35354 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
DPP4 P27487 1/20 0.43
FAP Q12884 1/20 0.43
DPP8 Q6V1X1 1/20 0.43
DPP9 Q86TI2 1/20 0.43
DPP7 Q9UHL4 1/20 0.43
ALPI P09923 1/20 0.43
PKM P14618 1/20 0.43
PTGS1 P23219 1/20 0.43
XIAP P98170 1/20 0.43
LTA4H P09960 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16060244 1.00 ALDH1A1 (0.51) ALDH1A1ATML3MBTL1ESR1ESR2
SCHEMBL10076449 1.00 ALDH1A1 (0.51) ALDH1A1ATML3MBTL1ESR1ESR2
Hydrochloric Acid SCHEMBL16060242 0.98 ALDH1A1 (0.53) ALDH1A1ATML3MBTL1ESR1ESR2
Hydrochloric Acid SCHEMBL16060240 0.98 ALDH1A1 (0.53) ALDH1A1ATML3MBTL1ESR1ESR2
SCHEMBL539211 0.95 TPH1 (0.48) ALDH1A1ATML3MBTL1ESR1ESR2
SCHEMBL539210 0.95 TPH1 (0.48) ALDH1A1ATML3MBTL1ESR1ESR2
Hydrochloric Acid SCHEMBL539863 0.94 ALDH1A1 (0.50) ALDH1A1ATML3MBTL1ESR1ESR2
Hydrochloric Acid SCHEMBL539862 0.94 ALDH1A1 (0.50) ALDH1A1ATML3MBTL1ESR1ESR2
SCHEMBL31686091 0.91 NOS2 (0.46) ALDH1A1ATML3MBTL1ESR1ESR2
SCHEMBL31686041 0.91 ACACB (0.59) ALDH1A1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106188224-A A kind of multiple target-point anti-cancer medicine and preparation method and application 广东工业大学 2016-12-07 CN claimed
EP-4282865-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) 2023-11-29 EP disclosed
CN-113692401-A Process for producing aromatic amino acid derivative 中外制药株式会社 2021-11-23 CN disclosed
WO-2020189540-A1 METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE 中外製薬株式会社 2020-09-24 WO disclosed
CN-106188224-B A kind of multiple target-point anti-cancer drug and the preparation method and application thereof GUANGDONG UNIVERSITY OF TECHNOLOGY (CN) 2019-10-29 CN disclosed
CN-106188224-A A kind of multiple target-point anti-cancer medicine and preparation method and application 广东工业大学 2016-12-07 CN disclosed
WO-2015023979-A1 DISCRETE PEG CONSTRUCTS EQUIP, LLC (US) 2015-02-19 WO disclosed
US-20140155355-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY, INC. 2014-06-05 US disclosed
US-20120015909-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2012-01-19 US disclosed
US-7956220-B2 MAO-B inhibitors useful for treating obesity JENRIN DISCOVERY (US) 2011-06-07 US disclosed
EP-2199300-A2 Peptidic compounds The University Of Wollongong (AU) 2010-06-23 EP disclosed
US-7649015-B2 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. (US) 2010-01-19 US disclosed
US-7439258-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD (CA) 2008-10-21 US disclosed
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds GILEAD SCIENCES, INC. 2007-01-11 US disclosed
US-7160874-B2 Phenylalanine derivatives AJINOMOTO CO., INC. (JP) 2007-01-09 US disclosed
US-20070004683-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015909-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY MAOB, MAOA, GPR119 ALDH1A1 399/4885ATM 2278/4885L3MBTL1 3737/4885
US-20070004683-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY MAOB, MAOA, GPR119 ALDH1A1 399/4885ATM 2278/4885L3MBTL1 3737/4885
US-20140155355-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY MAOB, MAOA, GPR119 ALDH1A1 399/4885ATM 2278/4885L3MBTL1 3737/4885
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds PPA1, PNP, PPME1 ALDH1A1 3337/4885ATM 1678/4885L3MBTL1 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.